JP2018502580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502580A5 JP2018502580A5 JP2017536513A JP2017536513A JP2018502580A5 JP 2018502580 A5 JP2018502580 A5 JP 2018502580A5 JP 2017536513 A JP2017536513 A JP 2017536513A JP 2017536513 A JP2017536513 A JP 2017536513A JP 2018502580 A5 JP2018502580 A5 JP 2018502580A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- clostridial toxin
- modified clostridial
- residue
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 231100001102 clostridial toxin Toxicity 0.000 claims 72
- 235000001014 amino acid Nutrition 0.000 claims 54
- 229940024606 amino acid Drugs 0.000 claims 50
- 150000001413 amino acids Chemical class 0.000 claims 50
- 238000012986 modification Methods 0.000 claims 50
- 230000004048 modification Effects 0.000 claims 50
- 238000000034 method Methods 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108030001720 Bontoxilysin Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- -1 D546 Substances 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 208000014094 Dystonic disease Diseases 0.000 claims 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims 4
- 208000004350 Strabismus Diseases 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000018198 spasticity Diseases 0.000 claims 4
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 102000000583 SNARE Proteins Human genes 0.000 claims 3
- 108010041948 SNARE Proteins Proteins 0.000 claims 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 3
- 208000010118 dystonia Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 230000005945 translocation Effects 0.000 claims 3
- 239000001884 Cassia gum Substances 0.000 claims 2
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 claims 2
- 239000002656 Distearyl thiodipropionate Substances 0.000 claims 2
- 239000004144 Ethoxylated Mono- and Di-Glyceride Substances 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 239000004111 Potassium silicate Substances 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 108030001722 Tentoxilysin Proteins 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 206010005159 blepharospasm Diseases 0.000 claims 2
- 230000000744 blepharospasm Effects 0.000 claims 2
- 206010006514 bruxism Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004174 erythrosine Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000010451 perlite Substances 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 239000001433 sodium tartrate Substances 0.000 claims 2
- 239000001587 sorbitan monostearate Substances 0.000 claims 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 239000001904 Arabinogalactan Substances 0.000 claims 1
- 239000001878 Bakers yeast glycan Substances 0.000 claims 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims 1
- 239000004140 Calcium stearoyl fumarate Substances 0.000 claims 1
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 208000029728 Eyelid disease Diseases 0.000 claims 1
- 239000004230 Fast Yellow AB Substances 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 239000004118 Natrolite-phonolite Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000004396 Octenyl succinic acid modified gum arabic Substances 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004237 Ponceau 6R Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 101100052669 Schizosaccharomyces pombe (strain 972 / ATCC 24843) N118 gene Proteins 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 239000004139 Sodium stearoyl fumarate Substances 0.000 claims 1
- 239000001882 Soybean hemicellulose Substances 0.000 claims 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 1
- 201000010829 Spina bifida Diseases 0.000 claims 1
- 208000006097 Spinal Dysraphism Diseases 0.000 claims 1
- 239000004138 Stearyl citrate Substances 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 208000016599 Uterine disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000013142 Writer cramp Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000010419 agar Nutrition 0.000 claims 1
- 239000000728 ammonium alginate Substances 0.000 claims 1
- 235000010407 ammonium alginate Nutrition 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 201000002898 anismus Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000000440 bentonite Substances 0.000 claims 1
- 239000000404 calcium aluminium silicate Substances 0.000 claims 1
- 239000004197 calcium inosinate Substances 0.000 claims 1
- 239000000292 calcium oxide Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 239000001679 citrus red 2 Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000005034 decoration Methods 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 201000002904 focal dystonia Diseases 0.000 claims 1
- 201000002865 focal hand dystonia Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000004120 green S Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 230000037315 hyperhidrosis Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 239000000231 karaya gum Substances 0.000 claims 1
- 235000010494 karaya gum Nutrition 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 206010029864 nystagmus Diseases 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000004175 ponceau 4R Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 208000026451 salivation Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 239000000264 sodium ferrocyanide Substances 0.000 claims 1
- 239000004317 sodium nitrate Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 239000004324 sodium propionate Substances 0.000 claims 1
- 239000001589 sorbitan tristearate Substances 0.000 claims 1
- 235000011078 sorbitan tristearate Nutrition 0.000 claims 1
- 235000019317 soybean hemicellulose Nutrition 0.000 claims 1
- 201000002849 spasmodic dystonia Diseases 0.000 claims 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000024033 toxin binding Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/050043 WO2016110662A1 (en) | 2015-01-09 | 2015-01-09 | Cationic neurotoxins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147451A Division JP6867452B2 (ja) | 2019-08-09 | 2019-08-09 | 陽イオン性神経毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502580A JP2018502580A (ja) | 2018-02-01 |
| JP2018502580A5 true JP2018502580A5 (enExample) | 2018-03-15 |
| JP6601922B2 JP6601922B2 (ja) | 2019-11-06 |
Family
ID=52424029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536513A Active JP6601922B2 (ja) | 2015-01-09 | 2015-01-09 | 陽イオン性神経毒 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10647750B2 (enExample) |
| EP (2) | EP3822286A1 (enExample) |
| JP (1) | JP6601922B2 (enExample) |
| CN (2) | CN116333068A (enExample) |
| DK (1) | DK3242884T3 (enExample) |
| ES (1) | ES2873479T3 (enExample) |
| HU (1) | HUE053935T2 (enExample) |
| PL (1) | PL3242884T3 (enExample) |
| PT (1) | PT3242884T (enExample) |
| RU (1) | RU2733493C2 (enExample) |
| TW (1) | TWI700289B (enExample) |
| WO (1) | WO2016110662A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| ES2893838T3 (es) | 2016-03-02 | 2022-02-10 | Merz Pharma Gmbh & Co Kgaa | Composición que comprende toxina botulínica |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| PL3481852T3 (pl) * | 2016-07-08 | 2023-07-24 | Children's Medical Center Corporation | Nowa neurotoksyna botulinowa i jej pochodne |
| TW201814045A (zh) * | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| RU2766147C2 (ru) * | 2017-03-22 | 2022-02-08 | Бонти, Инк. | Применение ботулинических нейротоксинов в лечении |
| EP3642222A1 (en) | 2017-06-20 | 2020-04-29 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| BR112021016324A2 (pt) * | 2019-02-20 | 2021-11-16 | Regresar Medical Inc | Métodos e dispositivos para localizar composições |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| BR112023020057A2 (pt) | 2021-03-30 | 2024-03-12 | Ipsen Biopharm Ltd | Tratamento de dor e distúrbios inflamatórios |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| EP1099445A3 (en) | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| WO2000067700A2 (en) * | 1999-05-12 | 2000-11-16 | United States Army Medical Research & Materiel Cmd | Recombinant vaccine against botulinum neurotoxin |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| AU4746096A (en) * | 1995-06-06 | 1996-12-24 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin |
| AU6326896A (en) * | 1996-03-08 | 1997-09-22 | Regents Of The University Of California, The | Chemically-modified clostridiatoxin with improved properties |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| AU755513B2 (en) | 1998-05-13 | 2002-12-12 | Merz Pharma Gmbh & Co. Kgaa | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| JP4454152B2 (ja) | 1998-07-22 | 2010-04-21 | オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド | 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物 |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| CA2380457A1 (en) | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| AU2003287155A1 (en) | 2002-10-15 | 2004-05-04 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US7172764B2 (en) | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| EP1773874B1 (en) * | 2004-08-04 | 2012-10-24 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| CA2595115C (en) | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| JP5167473B2 (ja) * | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| DK1926744T4 (en) | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| EP2038299A2 (en) * | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| AU2010236613B2 (en) | 2009-04-14 | 2016-07-07 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| AU2010267963B2 (en) | 2009-07-02 | 2015-09-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| CA2788074C (en) * | 2010-01-25 | 2016-07-12 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| CA2855173A1 (en) * | 2011-11-09 | 2013-05-16 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| US9315549B2 (en) * | 2013-01-28 | 2016-04-19 | New York University | Treatment methods using atoxic neurotoxin derivatives |
| US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
-
2015
- 2015-01-09 DK DK15701379.8T patent/DK3242884T3/da active
- 2015-01-09 ES ES15701379T patent/ES2873479T3/es active Active
- 2015-01-09 EP EP20210686.0A patent/EP3822286A1/en active Pending
- 2015-01-09 CN CN202211012695.6A patent/CN116333068A/zh active Pending
- 2015-01-09 PL PL15701379T patent/PL3242884T3/pl unknown
- 2015-01-09 HU HUE15701379A patent/HUE053935T2/hu unknown
- 2015-01-09 WO PCT/GB2015/050043 patent/WO2016110662A1/en not_active Ceased
- 2015-01-09 CN CN201580071947.4A patent/CN107108703B/zh active Active
- 2015-01-09 US US15/540,637 patent/US10647750B2/en active Active
- 2015-01-09 EP EP15701379.8A patent/EP3242884B1/en active Active
- 2015-01-09 JP JP2017536513A patent/JP6601922B2/ja active Active
- 2015-01-09 PT PT157013798T patent/PT3242884T/pt unknown
- 2015-01-09 RU RU2017128211A patent/RU2733493C2/ru active
- 2015-12-30 TW TW104144440A patent/TWI700289B/zh active
-
2020
- 2020-02-25 US US16/800,109 patent/US11014968B2/en active Active
-
2021
- 2021-04-19 US US17/301,897 patent/US12037369B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502580A5 (enExample) | ||
| RU2017128211A (ru) | Катионные нейротоксины | |
| JP2024012421A5 (enExample) | ||
| Raval et al. | Biochemical and structural characterization of a detergent-stable serine alkaline protease from seawater haloalkaliphilic bacteria | |
| CN101970658B (zh) | 耐热性过氧化氢酶 | |
| CN101506360B (zh) | 具有增加产率的支链淀粉酶变体 | |
| EP3130671A1 (en) | New protein deamidase | |
| JP2005517627A5 (enExample) | ||
| JP2019206582A5 (enExample) | ||
| Naidu | Characterization and purification of protease enzyme | |
| US7037696B1 (en) | Truncated form of fibrobacter succinogenes 1,3-1, 4-β-d-glucanase with improved enzymatic activity and thermo-tolerance | |
| JP2019531698A (ja) | 活性化クロストリジウム神経毒の製造 | |
| Oh et al. | Isolation of bacteria from chunggukjang prepared by rice straw and identification of protease secreted | |
| KR101190078B1 (ko) | 베타-아가레즈 재조합 발현 벡터, 형질전환 균주 및 베타-아가레즈 생산 방법 | |
| JP2023090955A5 (enExample) | ||
| JPWO2022189807A5 (enExample) | ||
| Hosseini | Isolation, Molecular Cloning, Expression and Bioinformatics Evaluation of aprX Serine Protease Gene Extracted from Bacillus licheniformis | |
| ABBASI et al. | Cloning and enhanced expression of an extracellular alkaline protease from a soil isolate of Bacillus clausii in Bacillus subtilis | |
| Kim et al. | Heterologous expression and secretion of sweet potato peroxidase isoenzyme A1 in recombinant Saccharomyces cerevisiae | |
| Liu XuDong et al. | Molecular cloning and characterization of an α-amylase with raw starch digestibility from Bacillus sp. YX-1. | |
| JP2025110393A (ja) | バイオポリマー製造方法 | |
| Gandhi et al. | Research Article Expression and Characterization of Geobacillus stearothermophilus SR74 Recombinant�-Amylase in Pichia pastoris | |
| Gegeckas | Characterization and application of keratinolytic peptidases from Geobacillus sp. and Bacillus spp | |
| TH2101001791A (th) | คลอสทริเดียลนิวโรทอกซินซึ่งประกอบรวมด้วยลูปการกระตุ้นแบบเอ็กโซจีเนียส | |
| GuoYing et al. | Cloning and heterologous expression of pro-2127, a gene encoding cold-active protease from Pseudoalteromonas sp. QI-1 |